Nevro (NVRO) Misses Q3 EPS by 8c, Revenues Beat; Offers FY18 Revenues Guidance 'At Low End of Previously Stated Range'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. HUMA
8. cASY
9. TSLA
10. CME

Go back to Nevro (NVRO) Misses Q3 EPS by 8c, Revenues Beat; Offers FY18 Revenues Guidance 'At Low End of Previously Stated Range'

Nevro Reports Third Quarter 2018 Financial Results

November 5, 2018 4:10 PM EST

REDWOOD CITY, Calif., Nov. 5, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three and nine months ended September 30, 2018.

Third Quarter Financial Results

Revenue for the three months ended September 30, 2018 was $95.6 million versus $82.3 million during the same period of the prior year, representing 16% growth as reported. U.S. revenue for the three months ended September 30, 2018 was $79.6 million, representing 20% growth. International revenue was $16.0 million, representing growth of 4% in constant... More